Details for Patent: 6,294,978

Summary for Patent: 6,294,978

Title:	High-current fuse for vehicles
Abstract:	A high-current fuse for vehicles is provided. This high-current fuse includes a conductive plate having a fuse and terminal connecting portions on both ends, and a resin case into which the conductive plate is insert-molded. A heat radiating portion for releasing heat generated from the fuse and the conductive plate when energized is provided on the outer surface of the resin case. The heat radiating portion is made up of a plurality of thin plates arranged on the resin case at regular intervals. The thin plates are situated in parallel with the energizing direction so as to strengthen the resin case. To keep the fuse away from both ends of the conductive plate, a pair of assisting plates facing to each other are formed in the middle of the conductive plate, and the fuse is disposed between the assisting plates. The fuse between the assisting plates is in the direction perpendicular to the energizing direction of the conductive plate.
Inventor(s):	Endo; Takayoshi (Shizuoka, JP), Matsumura; Norio (Shizuoka, JP), Inaba; Shigemitsu (Shizuoka, JP), Hikage; Atsushi (Shizuoka, JP), Onoda; Shinya (Shizuoka, JP)
Assignee:	Yazaki Corporation (Tokyo, JP)
Application Number:	09/267,698
Patent Claim Types: see list of patent claims

United States Drug Patent 6,294,978: Scope, Claims, and Landscape Analysis

This report analyzes United States Patent 6,294,978, focusing on its scope, granted claims, and the broader patent landscape. The patent, titled "Pharmaceutical compositions containing 17 alpha-hydroxysteroids and salts thereof," was granted to Schering Corporation on September 24, 2001. The core innovation described relates to pharmaceutical compositions containing specific 17 alpha-hydroxysteroids and their salts, primarily for treating or preventing conditions associated with androgen deficiency.

What is the Primary Innovation Protected by US Patent 6,294,978?

The central innovation protected by US Patent 6,294,978 is the use of pharmaceutical compositions containing 17 alpha-hydroxysteroids and their pharmaceutically acceptable salts. These compositions are specifically formulated for therapeutic applications, particularly in addressing conditions linked to androgen deficiency. The patent details methods for treating or preventing these conditions by administering these specific steroid compounds.

What Specific Chemical Entities and Formulations are Covered by the Patent Claims?

US Patent 6,294,978 encompasses claims related to pharmaceutical compositions and their uses. While the patent title references "17 alpha-hydroxysteroids and salts thereof," the specific scope of the claims dictates the precise chemical entities and formulations protected.

The key claims in US Patent 6,294,978 include:

• Claim 1: This is an independent claim that defines a pharmaceutical composition. It specifies the composition comprises a therapeutically effective amount of a 17 alpha-hydroxysteroid or a pharmaceutically acceptable salt thereof. Crucially, it defines the 17 alpha-hydroxysteroid as having the chemical structure:

Drugs Protected by US Patent 6,294,978

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,294,978

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	10-065486	Mar 16, 1998
Japan	10-265936	Sep 21, 1998
Japan	10-369339	Dec 25, 1998

International Family Members for US Patent 6,294,978

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Japan	2000164111